HENGRUIPHARMA：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025.pdf

1、Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relian

2、ce upon the whole or any part of the contents of this announcement.Jiangsu Hengrui Pharmaceuticals Co.,Ltd.江蘇恒瑞醫藥股份有限公司(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:1276)ANNUAL RESULTS ANNOUNCEMENT FORTHE YEAR ENDED DECEMBER 31,2025The board(

3、the“Board”)of directors(the“Directors”)of Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(the“Company”)is pleased to announce the audited annual results of the Company and its subsidiaries for the year ended December 31,2025.This announcement,containing the full text of the 2025 annual report of the Compan

4、y,is prepared with reference to the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to preliminary announcements of annual results.The Companys 2025 annual report is available for viewing on the websites of The Stock Excha

5、nge of Hong Kong Limited at https:/www.hkexnews.hk and of the Company at http:/.By order of the BoardJiangsu Hengrui Pharmaceuticals Co.,Ltd.江蘇恒瑞醫藥股份有限公司Mr.Sun PiaoyangChairmanShanghai,PRCMarch 25,2026As at the date of this announcement,the Board comprises:(i)Mr.Sun Piaoyang,Mr.Dai Hongbin,Ms.Feng J

6、i,Mr.Zhang Lianshan,Mr.Jiang Frank Ningjun and Mr.Sun Jieping as executive Directors;(ii)Ms.Guo Congzhao as non-executive Director;and(iii)Mr.Dong Jiahong,Mr.Zeng Qingsheng,Mr.Sun Jinyun and Mr.Chow Kyan Mervyn as independent non-executive Directors.Corporate Information2Financial Highlights4Corpora